Published in N Engl J Med on August 13, 1998
Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol (2010) 3.23
Improving efficiency of inferences in randomized clinical trials using auxiliary covariates. Biometrics (2008) 3.04
Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov (2010) 2.27
New advances in the management of acute coronary syndromes: 1. Matching treatment to risk. CMAJ (2001) 2.12
The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke (2008) 1.79
The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int (2006) 1.47
Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin. Blood (2012) 1.46
The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial. Am Heart J (2011) 1.39
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Curr Control Trials Cardiovasc Med (2001) 1.30
Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain. J Clin Invest (2009) 1.24
Integrin-dependent control of translation: engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets. J Cell Biol (1999) 1.21
Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J (2009) 1.21
Systematic adjudication of myocardial infarction end-points in an international clinical trial. Curr Control Trials Cardiovasc Med (2001) 1.17
Integrin αIIbβ3: from discovery to efficacious therapeutic target. Circ Res (2013) 1.11
Efficacy, safety and cost of new cardiovascular drugs: a survey. Eur J Clin Pharmacol (2003) 1.10
Fast FSR variable selection with applications to clinical trials. Biometrics (2008) 1.01
Evolving the use of peptides as components of biomaterials. Biomaterials (2011) 0.99
New advances in the management of acute coronary syndromes: 3. The role of catheter-based procedures. CMAJ (2002) 0.97
Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine. Wiley Interdiscip Rev Syst Biol Med (2012) 0.97
Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment. Heart (2003) 0.96
Microfluidic thrombosis under multiple shear rates and antiplatelet therapy doses. PLoS One (2014) 0.95
Targeting integrin and integrin signaling in treating thrombosis. Arterioscler Thromb Vasc Biol (2014) 0.93
12-lipoxygenase: a potential target for novel anti-platelet therapeutics. Cardiovasc Hematol Agents Med Chem (2011) 0.92
Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: diagnosis and treatment. Clin Res Cardiol (2006) 0.92
Irreversible platelet activation requires protease-activated receptor 1-mediated signaling to phosphatidylinositol phosphates. Mol Pharmacol (2009) 0.89
Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups. Heart (2006) 0.88
Percutaneous coronary intervention in elderly patients: is it beneficial? Tex Heart Inst J (2011) 0.88
A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. Thromb Res (2013) 0.88
The utility of upper endoscopy in patients with concomitant upper gastrointestinal bleeding and acute myocardial infarction. Dig Dis Sci (2006) 0.86
Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years. Circ Cardiovasc Qual Outcomes (2015) 0.85
Managing adverse effects and drug-drug interactions of antiplatelet agents. Nat Rev Cardiol (2011) 0.84
Risk stratification in acute coronary syndrome: focus on unstable angina/non-ST segment elevation myocardial infarction. Heart (2004) 0.84
Cardiovascular magnetic resonance of scar and ischemia burden early after acute ST elevation and non-ST elevation myocardial infarction. J Cardiovasc Magn Reson (2008) 0.84
International comparison of mortality rates in patients with non-ST elevation acute coronary events. Heart (2003) 0.83
Anti-platelet therapy: glycoprotein IIb-IIIa antagonists. Br J Clin Pharmacol (2011) 0.83
Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients. Eur Heart J Acute Cardiovasc Care (2013) 0.83
Eptifibatide-induced thrombocytopenia: with thrombosis and disseminated intravascular coagulation immediately after left main coronary artery percutaneous coronary angioplasty. Tex Heart Inst J (2012) 0.82
The impact of bleeding in patients with acute coronary syndromes: how to optimize the benefits of treatment and minimize the risk. Can J Cardiol (2007) 0.81
Clinical and economic studies of eptifibatide in coronary stenting. Ther Clin Risk Manag (2014) 0.81
[Costs caused by bleeds within the therapy of acute coronary syndromes in Germany]. Herz (2009) 0.81
Antiplatelet therapy from clinical trials to clinical practice. Clin Med Res (2003) 0.80
Low-molecular-weight heparins in the cardiac catheterization laboratory. Tex Heart Inst J (2004) 0.80
Acute profound thrombocytopenia with second exposure to eptifibatide associated with a strong antibody reaction. Platelets (2009) 0.80
Critical review of unstable angina and non-ST elevation myocardial infarction. Postgrad Med J (2002) 0.80
Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial. Heart (2003) 0.80
Eptifibatide: The evidence for its role in the management of acute coronary syndromes. Core Evid (2010) 0.80
Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part 2). Tex Heart Inst J (2010) 0.80
High Bolus Tirofiban vs Abciximab in Acute STEMI Patients Undergoing Primary PCI - The Tamip Study. Heart Views (2012) 0.79
Profound thrombocytopenia after primary exposure to eptifibatide. Drug Healthc Patient Saf (2010) 0.79
Decreased soluble cell adhesion molecules after tirofiban infusion in patients with unstable angina pectoris. Thromb J (2004) 0.78
Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both? Vasc Health Risk Manag (2006) 0.78
Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. J Am Heart Assoc (2015) 0.78
Eptifibatide induced profound thrombocytopenia in a patient with pelvic malignancy: A case report. Gynecol Oncol Case Rep (2012) 0.78
Glycoprotein IIb/IIIa inhibitors use and outcome after percutaneous coronary intervention for non-ST elevation myocardial infarction. Biomed Res Int (2014) 0.77
Antiplatelet treatment in unstable angina: aspirin, clopidogrel, glycoprotein IIb/IIIa antagonist, or all three? Heart (2002) 0.77
Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor. Mol Ther (2011) 0.77
Socio economic crisis and mortality. Epidemiological testimony of the financial collapse of Argentina. Thromb J (2005) 0.77
Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm. Can J Cardiol (2006) 0.76
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. Curr Control Trials Cardiovasc Med (2001) 0.76
Management of patients with unstable angina / non-ST-elevation myocardial infarction: a critical review of the 2007 ACC /AHA guidelines. Int J Clin Pract (2009) 0.76
Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics. Anesth Analg (2011) 0.76
Tolerability and feasibility of eptifibatide in acute coronary syndrome in patients at high risk for cardiovascular disease: A retrospective analysis. Curr Ther Res Clin Exp (2005) 0.76
Balancing potency of platelet inhibition with bleeding risk in the early treatment of acute coronary syndrome. West J Emerg Med (2009) 0.75
Eptifibatide in acute coronary syndromes. N Engl J Med (1999) 0.75
Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions. Curr Cardiol Rev (2012) 0.75
Debate: When should we intervene in unstable angina - Time for an old look? Curr Control Trials Cardiovasc Med (2000) 0.75
Multi-vessel coronary disease and percutaneous coronary intervention. Heart (2004) 0.75
Eptifibatide in acute coronary syndromes. N Engl J Med (1999) 0.75
Eptifibatide and Cirrhosis: Rethinking GPIIb-IIIa Inhibitors for Acute Coronary Syndrome in the Setting of Liver Dysfunction. Cardiol Res (2014) 0.75
Clinical review: bleeding - a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and management. Crit Care (2013) 0.75
Prognostic relevance of PCI-related myocardial infarction. Nat Rev Cardiol (2013) 0.75
Debate: Unstable angina - When should we intervene? Curr Control Trials Cardiovasc Med (2000) 0.75
Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review. Am J Cardiovasc Drugs (2015) 0.75
Update in internal medicine. Arch Med Res (2000) 0.75
Glycoprotein IIb/IIIa receptor antagonists: a review of the pivotal trials. Proc (Bayl Univ Med Cent) (2000) 0.75
ACHTUNG-Rule: a new and improved model for prognostic assessment in myocardial infarction. Eur Heart J Acute Cardiovasc Care (2012) 0.75
Learning on the Web. Case 3: acute chest pain. Heart (2004) 0.75
Explicit risk in acute coronary syndrome management. Can J Cardiol (2009) 0.75
Interventional pharmacotherapy. BMJ (2003) 0.75
Left main stent thrombosis complicated by eptifibatide-induced acute thrombocytopenia. Tex Heart Inst J (2011) 0.75
Angiographic and clinical outcomes of bivalirudin versus heparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Can J Cardiol (2006) 0.75
Variation in Practice Regarding Pretreatment With Dual Antiplatelet Therapy for Patients With Non-ST Elevation Myocardial Infarction. J Am Heart Assoc (2016) 0.75
Eptifibatide-induced acute profound thrombocytopenia: a case report. BMC Res Notes (2014) 0.75
Eptifibatide in acute coronary syndromes. N Engl J Med (1999) 0.75
Abciximab: a reappraisal of its use in coronary care. Biologics (2008) 0.75
Regular review: treatment possibilities for unstable angina. BMJ (2000) 0.75
Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update. Vasc Health Risk Manag (2010) 0.75
Unstable angina and non-ST-segment elevation myocardial infarction: perspectives on combination therapy. Tex Heart Inst J (2001) 0.75
Acute Severe Thrombocytopenia Occurring After Administration of Eptifibatide Postpones Emergent Coronary Artery Surgery. Anesth Pain Med (2016) 0.75
Management of acute coronary syndromes. BMJ (2000) 0.75
Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials. Circulation (2016) 0.75
[Percutaneous coronary angioplasty in women: clinical, procedural and prognostic features]. Pan Afr Med J (2011) 0.75